Jazz Pharmaceuticals files for gutsy $172M IPO
Jazz Pharmaceuticals, a Palo Alto, Calif. company that seeks to license drugs from other companies, buy other drug companies and develop its own drugs, all in the area neurology and psychiatry, has filed for a $172.5 million IPO.
Here is its filing. It is four years old, and lost $81 million last year.
This is largely a financial engineering strategy, and it will be interesting to see whether the public is willing to buy stock in such… Continue Reading